Estimation of airborne contamination during therapeutic radioiodine-131(I-131) administration: A comparative study between capsule and solution forms.
I-131 capsules reduce airborne contamination compared to solutions, ensuring compliance with radiation safety standards.
Where it sits
this study against the rest of the cjc-1295 with dac corpusSummary and findings
The study measured airborne contamination during therapeutic administration of I-131 in capsule and solution forms. It found significantly lower contamination levels with capsules. All concentrations were below the DAC limit of 416.7 Bq/m³.
Abstract
<h4>Background</h4>Radioiodine-131(I-131) is widely used in the treatment of thyroid diseases. Despite its therapeutic advantages, working with unsealed sources such as I-131poses risk of airborne contamination and occupational radiation exposure, especially from airborne contamination during the preparation and administration procedures.<h4>Objective</h4>This study aims to compare the airborne contamination levels during the administration of I-131in capsule and solution forms by estimating the Derived Air Concentration (DAC) during therapeutic procedures and evaluating occupational exposure risk.<h4>Materials and methods</h4>Airborne contamination was measured by using a portable air sampler is equipped with charcoal-impregnated cellulose filters during the dispensing and administration of therapeutic doses (range 50-200 mCi) of I-131.The collected samples were analysed by using a well counter based dose calibrator and a SPECT-CT machine. The DAC values were calculated and compared to the International radiation safety regulatory agencies like IAEA, ICRP prescribed limits.<h4>Results</h4>A total of 104 administrations were analysed over a period of 13months. Airborne contamination levels were significantly lower during the use of I-131capsules compared to solution form. Minimum airborne activity was 8.53Bq/m<sup>3</sup> (50 mCi of I-131 in capsule form), whereas a maximum contamination of 76.50 Bq/m<sup>3</sup> (200 mCi of I-131solution). All measured concentrations remained below DAC limit of 416.7 Bq/m<sup>3</sup> (P < 0.01).<h4>Conclusion</h4>I-131capsules significantly reduce airborne contamination and occupational exposure risks compared to solution form. The use of capsule-based therapies ensures good compliance with radiation safety standards (ICRP and IAEA recommendations).
Background
Radioiodine-131 (I-131) is commonly used for treating thyroid diseases, but poses risks of airborne contamination during preparation and administration. This study is important as it evaluates the occupational exposure risks associated with different forms of I-131 administration, specifically comparing capsule versus solution forms.
Methods
The study used a portable air sampler with charcoal-impregnated cellulose filters to measure airborne contamination during the administration of therapeutic doses (50-200 mCi) of I-131. Samples were analyzed using a dose calibrator and a SPECT-CT machine. The Derived Air Concentration (DAC) values were calculated and compared to international safety limits.
Results
The study analyzed 104 administrations over 13 months, finding significantly lower airborne contamination levels with capsules compared to solutions. The minimum airborne activity was 8.53 Bq/m³ with capsules, while the maximum was 76.50 Bq/m³ with solutions. All measured concentrations were below the DAC limit of 416.7 Bq/m³ (P < 0.01).
Interpretation
The findings suggest that using I-131 capsules reduces airborne contamination and occupational exposure risks compared to solutions. While the study shows statistically significant differences, the clinical significance is limited to compliance with safety standards, without addressing therapeutic efficacy. The results are consistent with regulatory guidelines but do not provide new insights into patient outcomes.
Key findings
- Airborne contamination significantly lower with capsules.
- Minimum airborne activity: 8.53 Bq/m³ (50 mCi capsule).
- Maximum contamination: 76.50 Bq/m³ (200 mCi solution).
- All concentrations below DAC limit of 416.7 Bq/m³.
- 104 administrations analyzed over 13 months.
Limitations
- Does not address long-term effects.
- Focuses on airborne contamination, not clinical outcomes.
- Single-site study.
- Short-term analysis over 13 months.